Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof

1. A compound of formula (I)

wherein

Y 1 is

A is aryl, heteroaryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroarylalkyl, heterocyclealkyl, cycloalkylalkyl, or cycloalkenylalkyl wherein the aryl, heteroaryl, cycloalkyl, cycloalkenyl, the aryl moiety of arylalkyl, the heteroaryl moiety of the heteroarylalkyl, the heterocycle moiety of the heterocyclealkyl, the cycloalkyl moiety of the cycloalkylalkyl, and the cycloalkenyl moiety of the cycloalkenylalkyl are each independently unsubstituted or substituted, wherein if A is a bicyclic aryl or bicyclic heteroaryl, the bicyclic aryl or bicyclic heteroaryl is selected from the group consisting of dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, tetrahydronaphthalenyl, and quinolin; and

Y 2 is hydrogen or alkyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein Y 2 is hydrogen, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein Y 1 is formula (b), or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein Y 2 is hydrogen, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , wherein Y 1 is (c), or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , wherein Y 2 is hydrogen, or a pharmaceutically acceptable salt thereof.

7. A compound selected from the group consisting of

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-methylphenyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-phenylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-1-naphthylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(3-chlorophenyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-tert-butylphenyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-[4-(trifluoromethoxy)phenyl]acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-[4-(trifluoromethyl)phenyl]acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-chloro-1-naphthyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-bromophenyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-pyridin-3-ylacetamide;

2-[-1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-pyridin-2-ylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-quinolin-6-ylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-chlorophenyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N2-naphthylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-chlorobenzyl)acetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-1,1′-biphenyl-4-ylacetamide;

2-[1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene]-N-(4-fluorophenyl)acetamide;

(4r)-N-(4-chlorophenyl)-1-azatricyclo[3.3.1.1 3,7 ]decane-4-carboxamide;

(4r)-N-2-naphthyl-1-azatricyclo[3.3.1.1 3,7 ]decane-4-carboxamide; and

(4r)-N-quinolin-6-yl-1-azatricyclo[3.3.1.1 3,7 ]decane-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers.

9. The pharmaceutical composition of claim 8 further comprising one or more atypical antipsychotics.